inclusion criteria: - 1. patients aged 18-65 hospitalized with sars-cov-2, diagnosed by a positive nasal or nasopharyngeal swab 2. men or women who are not pregnant, not breastfeeding, postmenopausal, naturally or surgically sterile, or who agree to use effective contraception during the course of the study. a postmenopausal patient is defined as at least 12 12 months of natural spontaneous amenorrhea or at least 6 weeks after surgical menopause (bilateral oophorectomy). 3. women of childbearing age who use one of the following acceptable contraceptive methods can be included in the study: surgical sterilization (hysterectomy and/or bilateral oophorectomy); surgical sterilization (surgical bilateral tubal ligation at least 6 weeks prior to screening); intrauterine device (iud) placed at least 3 months prior to detection; abstinence (not having heterosexual sex); barrier method (condom or diaphragm) with spermicide for at least 14 days before selection and until completion of the study; stable hormonal contraceptive for at least 3 months prior to selection and until completion of the study 4. patients capable of understanding and providing signed informed consent.

inclusion criteria: - 1. patients aged 18-65 hospitalized with sars-cov-2, diagnosed by a positive nasal or nasopharyngeal swab 2. men or women who are not pregnant, not breastfeeding, postmenopausal, naturally or surgically sterile, or who agree to use effective contraception during the course of the study. a postmenopausal patient is defined as at least 12 12 months of natural spontaneous amenorrhea or at least 6 weeks after surgical menopause (bilateral oophorectomy). 3. women of childbearing age who use one of the following acceptable contraceptive methods can be included in the study: surgical sterilization (hysterectomy and/or bilateral oophorectomy); surgical sterilization (surgical bilateral tubal ligation at least 6 weeks prior to screening); intrauterine device (iud) placed at least 3 months prior to detection; abstinence (not having heterosexual sex); barrier method (condom or diaphragm) with spermicide for at least 14 days before selection and until completion of the study; stable hormonal contraceptive for at least 3 months prior to selection and until completion of the study 4. patients capable of understanding and providing signed informed consent.